S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
REV Group Shifts Into High Gear: Double-Digit Upside Ahead
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
REV Group Shifts Into High Gear: Double-Digit Upside Ahead
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
REV Group Shifts Into High Gear: Double-Digit Upside Ahead
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 EV Stocks You Need To Have On Your Watchlist
3 Mid Caps You Haven't Heard Of But Need To Know About
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
REV Group Shifts Into High Gear: Double-Digit Upside Ahead

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$24.95
+1.49 (+6.35%)
(As of 09:01 AM ET)
Compare
Today's Range
$24.95
$24.95
50-Day Range
$16.59
$23.46
52-Week Range
$9.50
$24.95
Volume
2,106 shs
Average Volume
777,963 shs
Market Capitalization
$2.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.09

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.8% Upside
$51.09 Price Target
Short Interest
Bearish
10.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.43mentions of Rocket Pharmaceuticals in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$43,678 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.08) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

196th out of 986 stocks

Pharmaceutical Preparations Industry

87th out of 486 stocks


RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
See More Headlines

RCKT Price History

RCKT Company Calendar

Last Earnings
5/04/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
151
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$51.09
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+117.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.47 per share

Miscellaneous

Free Float
55,438,000
Market Cap
$1.89 billion
Optionable
Optionable
Beta
1.22

Social Links


Key Executives

  • Gaurav D. ShahGaurav D. Shah
    Chief Executive Officer & Director
  • Kinnari Patel
    President & Chief Operating Officer
  • John C. Militello
    Treasurer, Chief Financial & Accounting Officer
  • Mayo Pujols
    Chief Technical Officer & Executive Vice President
  • Mark White
    Chief Medical Officer













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 analysts have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they predict the company's share price to reach $51.09 in the next twelve months. This suggests a possible upside of 117.8% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT shares have increased by 19.9% and is now trading at $23.46.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.11. During the same period in the previous year, the business earned ($0.67) EPS.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Maverick Capital Ltd. (5.48%), Wellington Management Group LLP (5.11%), State Street Corp (5.00%), Westfield Capital Management Co. LP (4.02%) and Price T Rowe Associates Inc. MD (2.32%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $23.46.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.89 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -